Healthcare Equipment and Supplies
Company Overview of Autonomic Technologies, Inc.
Autonomic Technologies, Inc., a medical device company, develops medical implants. Its products include miniaturized implantable neurostimulation devices that provide rapid relief from the debilitating pain and suffering caused by severe headaches. The company was founded in 2007 and is based in Redwood City, California.
3698 Haven Avenue
Redwood City, CA 94063
Founded in 2007
Key Executives for Autonomic Technologies, Inc.
Vice President of Clinical & Regulatory
Vice President of Clinical Affairs
Vice President of Quality Assurance & Regulatory Compliance
Compensation as of Fiscal Year 2013.
Autonomic Technologies, Inc. Key Developments
Autonomic Technologies, Inc. Presents at IN3 Med Device 360° - Boston, Jun-25-2013 08:55 AM
Jun 6 13
Autonomic Technologies, Inc. Presents at IN3 Med Device 360° - Boston, Jun-25-2013 08:55 AM. Venue: The Hyatt Boston, One Avenue De Lafayette, Boston, MA 02111, United States.
Autonomic Technologies, Inc. Announces Results of Clinical Study in Cluster Headache
Feb 5 13
Autonomic Technologies, Inc. announced results of their clinical study in cluster headache. The robust, multi-centre, randomized, placebo-controlled clinical study is the study performed with a medical device for cluster headache. The ATI Neurostimulation System includes a novel, miniaturized device that is implanted using oral surgery, leaving no externally visible scars. When the patient feels a cluster attack beginning, they hold a remote controller up to their cheek to begin the neurostimulation therapy. The study showed that the ATI Neurostimulation System demonstrated clinical effectiveness in treating cluster headache, and provided significant improvement in patient quality of life and headache disability. The results were statistically significant: Pain relief at 15 minutes was achieved in 67.1% of treated attacks compared to 7.4% of sham treated attacks (p<0.0001), Pain freedom at 15 minutes was achieved in 34.1% of treated attacks compared to 1.5% of sham treated attacks (p<0.0001). The average number of cluster attacks per week was reduced by 31% (p=0.005), and 43% of patients experienced an average reduction of 88% in the number of attacks suffered, 64% of patients experienced clinically significant improvement in headache disability (HIT-6), 75% of patients experienced clinically significant improvements in quality of life (SF-36v2 physical and/or mental component scores), Acute rescue medications were used in only 31.0% of treated attacks compared to 77.4% of sham treated attacks (p<0.0001), a reduction of 60%. The ATI Neurostimulation System was well tolerated, and side effects were comparable to other similar surgical procedures and tended to be transient. Cluster headache is one of the most painful types of headache. Patients may experience multiple attacks daily or almost daily, associated with excruciating pain typically in the area of one eye. Each attack can last between 15 minutes and three hours.(1) Often called 'suicide headaches' because of their severity,(2) it is estimated that over 600,000 people across Europe suffer from cluster headaches. The ATI Neurostimulation System is a novel, rechargeable system, with an implantable neurostimulator that is smaller than an almond. Designed for the treatment of severe headache, the neurostimulator is activated using an external remote controller (similar in size to a smart phone), allowing patients to deliver as-needed stimulation to relieve the attack. After a headache is treated, the remote controller is simply moved away from the cheek, turning off stimulation therapy.
Autonomic Technologies Initiates European Study of Novel Neurostimulator for the Treatment of Severe Migraine
Feb 27 12
Autonomic Technologies Inc. announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine. The multi-center, randomized Pathway M-1 study will enroll 30 patients initially at leading headache centers in Denmark, Belgium, Spain, France and Germany. Migraine is the most common disabling headache, affecting 11% of the population in Western Europe and the United States. It is marked by pulsating, moderate to severe pain lasting from 4-72 hours, and may be associated with nausea and sensitivity to light or sound. The ATI Neurostimulation System is also currently being evaluated in the Pathway CH-1 study for the treatment of cluster headache, an extremely severe headache disorder. Interim results of this study were presented at the North American Neuromodulation Society meeting in December 2011 by Prof. Dr. Jean Schoenen, coordinator of the Headache Research Unit at University of Liege in Belgium. These interim results demonstrated pain relief in 59% of headaches treated. An important additional finding was a >=50% reduction in headache frequency in 63% of patients treated. The investigational ATI Neurostimulation System is a novel, rechargeable system, with a miniaturized implantable stimulator approximately the size of an almond that is designed for the treatment of severe headache, including cluster headache and migraine. The neurostimulator is delivered through a surgical incision in the gum, leaving no external scars. The lead tip of the implant is placed at the sphenopalatine ganglion (SPG) nerve bundle deep in the face on the predominant side of the headache. For years clinicians have targeted the SPG to relieve severe headache, primarily by applying lidocaine and other agents to achieve a nerve block. Using an external remote controller similar in size to a large cell phone, patients deliver as-needed stimulation to relieve the headache. After the headache is treated, the remote controller is simply moved away from the cheek, turning off stimulation therapy. The multi-center, randomized Pathway M-1 study will begin in leading headache centers in Denmark, Belgium, Spain, France and Germany. Additional European centers will be added later in the year. The study will enroll at least 30 patients who have a minimum of 4 migraine attacks per month and experience migraine pain on at least 8 days per month.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|